• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Pembrolizumab plus chemotherapy improves survival in patients with metastatic triple-negative breast cancer

byConstance Wu
December 15, 2020
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. First line treatment with pembrolizumab-chemotherapy showed significant improvement in progression-free survival compared to chemotherapy alone in patients with metastatic triple-negative breast cancer and a CPS of 10 or more.

2. There was no significant increase in adverse events or death with the addition of pembrolizumab to standard first-line chemotherapy.

 Evidence Rating Level: 1 (Excellent)

Study Rundown: Triple-negative breast cancer is challenging to treat due to the absence of targets for therapeutic intervention. Cytotoxic chemotherapy remains the standard treatment for most patients, but these tumours become rapidly resistant to chemotherapy. Pembrolizumab is an anti-PD-1 monoclonal antibody which has shown promising anti-tumour activity across many tumour types with an acceptable safety profile. This randomized controlled phase 3 clinical trial aimed to evaluate the efficacy and safety of pembrolizumab plus chemotherapy to chemotherapy alone in patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Results suggested that pembrolizumab-chemotherapy resulted in significant, clinically meaningful improvements in progression-free survival compared to chemotherapy alone in patients with CPS ≥10. The benefits on progression-free survival were consistent across pre-defined subgroups including type of chemotherapy and disease-free interval. Treatment related adverse event rates were similar between groups. A key strength of the current study comes from its inclusion of both taxanes and platinum-based chemotherapy regimens allowing for the assessment of pembrolizumab in combination with different chemotherapy agents. However, the subgroup analysis showing persistent benefit of pembrolizumab irrespective of chemotherapy partner was underpowered and, as such, the results of subgroup analysis should be interpreted with caution.

Click to read the study in The Lancet

Relevant Reading: Pembrolizumab for Early Triple-Negative Breast Cancer

RELATED REPORTS

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

Breast cancer survivors may have a lower risk of Alzheimer’s dementia

In-Depth [randomized controlled trial]: This randomized, placebo-controlled, double-blind, phase 3 clinical trial done in 209 sites in 29 countries around the world included adults aged >18 years of age with untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Participants were randomized to pembrolizumab (200 mg) every 3 weeks plus chemotherapy (one of nab-paclitaxel, paclitaxel, or gemcitabine plus carboplatin) or placebo plus chemotherapy. Randomization was stratified by type of chemotherapy, PD-L1 expression at baseline (combined positive score (CPS) ≥1 or <1), or previous treatment by the same class of chemotherapy in adjuvant or neoadjuvant setting. The primary efficacy endpoints of this study were progression-free survival and overall survival in the intention-to-treat and subgroup analysis.

A total of 847 patients (median age=53) were randomly assigned to treatment with 566 patients in the pembrolizumab-chemotherapy group and 281 patients the placebo-chemotherapy group. Overall, among patients with CPS ≥10, median progression-free survival was 9.7 months on pembrolizumab-chemotherapy compared to 5.6 months on placebo-chemotherapy (hazard ratio [HR] for progression or death 0.65, 95% CI 0.49 to 0.86; p=0.0012). In patients with CPS of 1 or more, median progression-free survival was 7.6 months in the pembrolizumab-chemotherapy group and 5.6 months in the placebo-chemotherapy group (HR 0.74, 95% CI 0.61 to 0.90; p=0.0014 [not significant]). Adverse events considered to be related to study treatment occurred in 96% of patients in the pembrolizumab-chemotherapy group compared to 95% in the placebo-chemotherapy group with anemia (49% vs. 46%), neutropenia (41% vs. 38%) and nausea (39% vs. 41%) being the most common side effects noted. Death occurred in <1% of the pembrolizumab-chemotherapy group compared to 0% in the placebo-chemotherapy group.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Breast Cancerchemotherapypdl-1Pembrolizumabtriple negative breast cancer
Previous Post

Febuxostat is not associated with worse cardiovascular safety outcomes or all-cause mortality compared to allopurinol

Next Post

#VisualAbstract: Oxygenated hypothermic perfusion reduces post-kidney transplant complications

RelatedReports

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
StudyGraphics

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

July 9, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025
Chronic Disease

Breast cancer survivors may have a lower risk of Alzheimer’s dementia

July 2, 2025
3D mammography (tomosynthesis) enhances accuracy of breast cancer screening
Chronic Disease

Abbreviated MRI is superior to whole-breast ultrasound for detection of cancer in dense breasts

June 25, 2025
Next Post
#VisualAbstract: Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease

#VisualAbstract: Oxygenated hypothermic perfusion reduces post-kidney transplant complications

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

Association between low density lipoprotein and all cause and cause specific mortality in Denmark

#VisualAbstract: Trends in positive BRCA results among older women between 2008 to 2018

#VisualAbstract: Trends in positive BRCA results among older women between 2008 to 2018

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind July 14, 2025
  • New obesity framework may reclassify over half of overweight individuals as people with obesity
  • Digital health apps may have limited role in reduction of migraine symptoms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.